The annual NHS drug bill stands at £13.8bn per annum1, and NICE has estimated that £4bn of medicines are not used correctly2. With the successful treatment of a disease depending on consistent use of medicines as prescribed, non-adherence is a pertinent issue for all healthcare stakeholders. Patients who do not adhere to their treatment are also at risk of increased hospitalization, resulting in further unnecessary costs to the healthcare economy.
We have spoken in previous blogs about the
value relationship that needs to exist between biopharma and the NHS (both payers and providers), and the need for biopharma to help those payers and providers develop confidence to use a new product. Biopharma needs to address two related, but different, concerns:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.